- Conditions
- Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Interventions
- Cytarabine, Decitabine, Idarubicin, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment, Questionnaire Administration, Azacitidine, Venetoclax, glasdegib
- Drug · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1393–1416
of 5,568
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colon Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Recurrent Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma
- Interventions
- Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride
- Drug · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Tampa, Florida • New Brunswick, New Jersey • Buffalo, New York + 1 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- Selinexor, Irinotecan
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- HIV, AIDS
- Interventions
- Kaletra (drug)
- Drug
- Lead sponsor
- Lampiris, Harry W., M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 59 Years · Male only
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Aspiration, Aspiration Pneumonia
- Interventions
- Ceftriaxone, Amoxicillin clavulanic acid, Cefepime, Vancomycin, Levofloxacin
- Drug
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Breast Cancer
- Interventions
- Palbociclib, Fulvestrant, Adjuvant Therapy
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 15 more
- Conditions
- Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
- Interventions
- inupadenant, Placebo, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- iTeos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Tampa, Florida
- Conditions
- HIV Infections, AIDS-Associated Nephropathy
- Interventions
- Nelfinavir mesylate, Saquinavir, Lamivudine, Stavudine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatitis C
- Interventions
- BMS-650032, BMS-790052
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Prostate Cancer
- Interventions
- Focal brachytherapy with PSMA PET imaging, (18F)DCFPyL
- Radiation · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Neuroendocrine Tumors
- Interventions
- Bevacizumab, Temozolomide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Heroin Dependence
- Interventions
- Buprenorphine/naloxone
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypothermia
- Interventions
- dexmedetomidine, buspirone, Bus and Dex, Control
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- HIV
- Interventions
- Lopinavir/ritonavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Weeks and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- La Jolla, California • Aurora, Colorado • Boston, Massachusetts
- Conditions
- Glioblastoma Multiforme, Gliosarcoma
- Interventions
- Avastin, Temozolomide, Irinotecan
- Drug
- Lead sponsor
- Katy Peters
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Obesity, Cardiovascular Diseases, Hypertension, Nocturnal Blood Pressure, Natriuretic Peptides, Renin-Angiotensin-Aldosterone System
- Interventions
- Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet, Valsartan 80 mg Oral Tablet
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Standard of Care, NeoThelium FT
- Other
- Lead sponsor
- NuScience Medical Biologics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 8
- States / cities
- Alexandria, Louisiana • Franklinton, Louisiana • Hammond, Louisiana + 5 more
- Conditions
- Contraception
- Interventions
- Eutectic Lidocaine Prilocaine, Subcutaneous Lidocaine
- Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Locally Advanced/Metastatic Solid Tumors
- Interventions
- BJ-001, Pembrolizumab
- Drug
- Lead sponsor
- BJ Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • New York, New York • Greenville, South Carolina + 2 more
- Conditions
- Parkinson's Disease
- Interventions
- Levodopa, Zolpidem first dose, Zolpidem second dose, sugar pill
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 30 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Moderate to Severe Opioid Use Disorder
- Interventions
- INDV-6001, Suboxone, Sublocade
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- San Diego, California • Miami Lakes, Florida • Chicago, Illinois + 8 more
- Conditions
- Diabetic Macular Edema
- Interventions
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 51
- States / cities
- Mesa, Arizona • Tucson, Arizona • Arcadia, California + 48 more
- Conditions
- HIV/AIDS Treatment, HIV Infections
- Interventions
- lopinavir/ritonavir (Kaletra®) tablets
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 6 Years to 17 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- San Diego, California • Washington D.C., District of Columbia